Fluarix Quadrivalent vs mRNA-1010: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
Measures 6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note | Source |
|---|---|---|---|---|---|---|
| Risk in group 1 | 0.0442 | 0.0405 | 0.0482 | wilson | ClinicalTrials.gov | |
| Risk in group 2 | 0.0462 | 0.0425 | 0.0503 | wilson | ClinicalTrials.gov | |
| Risk difference, group 1 minus group 2 | -0.00201 | -0.00746 | 0.00343 | newcombe hybrid score | ClinicalTrials.gov | |
| Risk ratio, group 1 over group 2 | 0.956 | 0.848 | 1.08 | log | ClinicalTrials.gov | |
| Odds ratio, group 1 over group 2 | 0.954 | 0.841 | 1.08 | log | ClinicalTrials.gov | |
| Number needed to treat, for one fewer participant with a serious adverse event on Fluarix Quadrivalent than on mRNA-1010 | 497 | from the risk difference interval | the interval includes no difference | ClinicalTrials.gov |
Groups 2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code | Source |
|---|---|---|---|---|---|---|
| Group 1 | Fluarix Quadrivalent | Participants received a single dose of Fluarix Quadrivalent by IM injection on Day 1. | 495 | 11,200 | EG000 | ClinicalTrials.gov |
| Group 2 | mRNA-1010 | Participants received a single dose of mRNA-1010 by IM injection on Day 1. | 518 | 11,210 | EG001 | ClinicalTrials.gov |
Harm 2
| Field | Value | Source |
|---|---|---|
| What it counts | Total, serious adverse events | ClinicalTrials.gov |
| Time frame | Day 1 up to the end of the study (Day 361) | ClinicalTrials.gov |
Trial 8
| Field | Value | Source |
|---|---|---|
| Title | A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults 50 Years Old and Older | ClinicalTrials.gov |
| NCT number | NCT05566639 | ClinicalTrials.gov |
| Phases | PHASE3 | ClinicalTrials.gov |
| Conditions | Seasonal Influenza | ClinicalTrials.gov |
| Interventions | mRNA-1010, Fluarix Quadrivalent | ClinicalTrials.gov |
| Lead sponsor | ModernaTX, Inc. | ClinicalTrials.gov |
| Results first posted | 2025-01-16 | ClinicalTrials.gov |
| Results on ClinicalTrials.gov | https://clinicaltrials.gov/study/NCT05566639?tab=results | ClinicalTrials.gov |
Source 4
| Field | Value | Source |
|---|---|---|
| Release | trial-comparisons-2026-03-23-0.1.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57 | ClinicalTrials.gov |
| AACT copy | 2026-03-23 | ClinicalTrials.gov |
| Tables read | outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet | ClinicalTrials.gov |
Release trial-comparisons-2026-03-23-0.1.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.